Showing results (71-80 of 127) with videos related to
Sort By:
Pageof 13
Biochemical and Biophysical Research Communications|January 26, 2007
Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surfaceRyo Uchida, Eishi Ashihara, Kiyoshi Sato, et al.The Journal of Antimicrobial Chemotherapy|February 16, 2008
Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysisKenichi Nomura, Norifumi Morikawa, Kazuro Ikawa, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 19, 2007
[Prophylactic effect of tropisetron hydrochloride against nausea and vomiting in patients receiving chemotherapy for hematological malignancies]Kenichi Nomura, Yoshiko Fujimoto, Kyoko Taniguchi, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 18, 2007
[Combination therapy with rituximab and cladribine for patients with follicular lymphoma]Yutaka Kobayashi, Yoshihide Murotani, Nana Sawai, et al.Biological & Pharmaceutical Bulletin|August 4, 2020
Factors Associated with Dose Modification of Lenalidomide Plus Dexamethasone Therapy in Multiple MyelomaYoko Kado, Masayuki Tsujimoto, Shin-Ichi Fuchida, et al.International Journal of Hematology|February 6, 2020
A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in JapanShin-Ichi Fuchida, Daisuke Ide, Yoko Taminishi-Katsuragawa, et al.European Journal of Haematology|August 4, 2004
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myelomaHirokazu Murakami, Hiroshi Fujii, Tohru Inaba, et al.Acta Haematologica|March 26, 2014
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma NetworkShuji Ozaki, Takeshi Harada, Takayuki Saitoh, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 4, 2004
[Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group]Hirokazu Murakami, Hiroshi Handa, Kohzoh Imai, et al.International Journal of Hematology|October 5, 2018
A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myelomaShin-Ichi Fuchida, Kazutaka Sunami, Morio Matsumoto, et al.Pageof 13